Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Eikon Therapeutics, Inc. (EIKN) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Pembrolizumab, Paclitaxel + Carboplatin, Nab-Paclitaxel + Carboplatin, Eik1001, Pemetrexed + Cisplatin /CarboplatinNon Small Cell Lung Cancer (Squamous Or Non Squamous), Stage 4 Nsclcphase2AndPhase3RecruitingA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.Jan 22, 2026
Pembrolizumab, Eik1005Advanced Solid Tumors, Endometrial Cancer, Mismatch Repair Deficient Or Msi-High Solid Tumors, Msi-H/Dmmr Colorectal Cancer, Msi-H Or Dmmr Advanced Solid Tumors, Msi-H/Dmmr Gastric Cancer, Msi-H/Dmmr Gastroesophageal-Junction Cancerphase1AndPhase2RecruitingEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsNov 10, 2025―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Eikon Therapeutics, Inc. (EIKN) have in its pipeline
Eikon Therapeutics, Inc. EIKN is currently developing the following drugs: Pembrolizumab, Paclitaxel + Carboplatin, Nab-Paclitaxel + Carboplatin, Eik1001, Pemetrexed + Cisplatin /Carboplatin, Pembrolizumab, Eik1005. These drug candidates are in various stages of clinical development as the company works toward FDA approval.